CohBar Appoints Carol Nast to Its Board of Directors
16. August 2021 09:00 ET
|
CohBar, Inc.
MENLO PARK, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
CohBar Reports Second Quarter 2021 Financial Results and Provides Business Update
10. August 2021 16:04 ET
|
CohBar, Inc.
MENLO PARK, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
CohBar Announces Positive Topline Results from the Phase 1a/1b Study of CB4211 Under Development for NASH and Obesity
10. August 2021 16:02 ET
|
CohBar, Inc.
CB4211 was well-tolerated and appeared safe with no serious adverse eventsRobust reductions in ALT and AST Reduction in glucose and trend towards body weight reductionCompany to host conference call...
CohBar to Announce 2021 Second Quarter Financial Results and Provide Business Update on August 10, 2021
04. August 2021 16:05 ET
|
CohBar, Inc.
MENLO PARK, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
CohBar Provides Update on the Phase 1a/1b Clinical Trial for CB4211 Under Development for NASH and Obesity
14. Juli 2021 09:00 ET
|
CohBar, Inc.
MENLO PARK, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
CohBar to Present at the BIO 2021 Digital Conference
10. Juni 2021 09:00 ET
|
CohBar, Inc.
MENLO PARK, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
CohBar Reports First Quarter 2021 Financial Results and Provides Business Update
17. Mai 2021 16:02 ET
|
CohBar, Inc.
MENLO PARK, Calif., May 17, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
CohBar to Announce 2021 First Quarter Financial Results and Provide Business Update on May 17, 2021
03. Mai 2021 09:00 ET
|
CohBar, Inc.
MENLO PARK, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
CohBar Appoints Joseph J. Sarret, M.D., J.D. as Chief Executive Officer and Director
27. April 2021 08:30 ET
|
CohBar, Inc.
MENLO PARK, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
CohBar Completes Last Subject Visit in the Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity
21. April 2021 09:00 ET
|
CohBar, Inc.
MENLO PARK, Calif., April 21, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...